{
    "nctId": "NCT01874522",
    "briefTitle": "Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI",
    "officialTitle": "A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Solid Tumors (Excluding Breast Cancer)",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (Cmax)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Has provided written informed consent\n2. Has advanced solid tumors (excluding breast cancer) for which no standard therapy exists\n3. ECOG performance status of 0 or 1\n4. Is able to take medications orally\n5. Has adequate organ function (bone marrow, kidney and liver)\n6. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.\n\nExclusion Criteria:\n\n1. Has had certain other recent treatment e.g. anticancer therapy, received investigational agent, within the specified time frames prior to study drug administration\n2. Certain serious illnesses or medical condition(s)\n3. Has had either partial or total gastrectomy\n4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies\n5. Known sensitivity to TAS-102 or its components\n6. Is a pregnant or lactating female\n7. Refuses to use an adequate means of contraception (including male patients)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}